# US 2017/0281607 A1 · Pharmaceutical compositions and methods for the treatment of diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281607 A1
- Document ID: US20170281607A1
- Status: Published application
- Kind: A1
- Application number: 15/474,430
- Filed: 2017-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: University of Limerick
- Applicants: University of Limerick
- Inventors: Mark Davies
- Web page: https://patentgrep.com/patent/US20170281607A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/428: condensed with carbocyclic rings
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 38/28: Insulins
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to compositions and methods for treating type I diabetes. Compositions of the invention include active compounds such as harmine, INDY, or derivatives thereof to induce reproduction of beta cells. These active compounds are provided in amounts that have poor clinical efficacy on their own, but when administered at a sub-threshold dose in combination with compounds such as insulin, which helps to maintain steady levels of insulin in the body; metformin, which decreases glucose levels; and repaglinide, which increases insulin production, allow for the slow and steady increase of beta cells.

## Claims

### Claim 1

A pharmaceutical composition comprising:
harmine in an amount insufficient to stimulate pancreatic beta cell production if administered alone in a single dose; and
a pharmaceutically-acceptable excipient.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising one or more compounds selected from the group consisting of insulin, metformin, and repaglinide.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said amount of harmine is between about 0.1 mg/kg and 10 mg/kg.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the insulin is present in an amount of from about 20 pmol/l to about 90 pmol/l.

### Claim 5 (depends on 2)

The composition of claim 2, wherein repaglinide and/or metformin is present in an amount below a threshold dose necessary to stimulate insulin production when administered alone.

### Claim 6 (depends on 1)

The composition of claim 1, wherein at least one of harmine, insulin, metformin, and repaglinide is present in a pro-drug form.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said harmine is conjugated to a blocking group selected from a hydroxyl group, an amine group, a carboxyl group, a carbonyl group, and an amide group.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said harmine is conjugated to an acetate blocking group as indicated below:
wherein R1is C2H3O and R2 is H; or R1 is H and R2 is C2H3O.

### Claim 9

A pharmaceutical composition comprising:
harmine or INDY in an amount that would be insufficient to stimulate pancreatic beta cell production in a single administration to a patient when the concentration of harmine in the patient is zero.

### Claim 10 (depends on 9)

The composition of claim 9, wherein said amount of harmine is less than about 1.0 mg/kg.

### Claim 11 (depends on 9)

The composition of claim 9, further comprising one or more compounds selected from the group consisting of insulin or an analog thereof, repaglinide, and metformin.

### Claim 12 (depends on 11)

The composition of claim 11, wherein repaglinide and/or metformin is present in an amount below a threshold dose necessary to stimulate insulin production when administered alone.

### Claim 13 (depends on 9)

The composition of claim 9, wherein harmine is present in a pro-drug form.

### Claim 14 (depends on 11)

The composition of claim 11, wherein at least one of said harmine, insulin, repaglinide, or metformin is present in a pro-drug form.

### Claim 15 (depends on 9)

The composition of claim 9, wherein said harmine is conjugated to an acetate protecting group.

### Claim 16 (depends on 15)

The composition of claim 15, wherein said harmine conjugated to an acetate blocking group comprises the formula:
wherein R1is C2H3O and R2 is H; or R1 is Hand R2 is C2H3O.

### Claim 17 (depends on 9)

The composition of claim 9, wherein said harmine is present in an amount of from about 0.1 mg/kg to 10 mg/kg.

### Claim 18 (depends on 1)

The composition of claim 1, wherein said composition is provided in a controlled release dosage form.

### Claim 19 (depends on 1)

The composition of claim 1, wherein said composition is formulated to be administered once a day.

### Claim 20

A pharmaceutical composition comprising:
harmine in an amount insufficient to cause psychotoxic effects;
one or more compounds selected from the group consisting of insulin or an analog thereof, metformin, and repaglinide; and
a pharmaceutically-acceptable excipient.
